Finland-based Orion Pharma announced receipt of orphan drug designation (ODD) from the US FDA for ODM-212, an oral small molecule pan-TEAD inhibitor. The indication linked to the ODD is mesothelioma.
The designation provides development incentives including tax credits, user-fee exemptions, and, if ultimately approved for the indication, seven years of US orphan exclusivity.
ODM-212 is an oral small-molecule pan-TEAD (Transcriptional Enhanced Associate Domain) inhibitor that targets the Hippo signaling pathway. Its mechanism operates through two distinct interactions: disrupting YAP-TEAD protein-protein interactions and inhibiting TEAD auto-palmitoylation, a post-translational modification required for TEAD transcriptional activity. Dysregulation of YAP and TAZ — the primary effectors downstream of Hippo — is implicated in tumor growth and resistance to existing therapies across several solid tumor types, including malignant pleural mesothelioma (MPM).
The ODD was granted broadly for mesothelioma. Orion’s active clinical program focuses specifically on MPM, along with epithelioid hemangioendothelioma (EHE) and other solid tumors carrying Hippo pathway dysfunction, in patients who have progressed after standard treatments and have no remaining options.
ODM-212 is currently being evaluated in a first-in-human Phase I/II study (NCT06725758) in selected advanced solid tumors. The trial is recruiting across sites in the United Kingdom, Finland, France, Switzerland, and the United States, with the Royal Marsden Hospital among the listed centers. The study’s primary endpoints are safety and tolerability, with secondary endpoints including overall response rate, progression-free survival, and overall survival. The program carries the same protocol across multiple registry identifiers, including ISRCTN99739590 and CTIS 2022-503061-29-00, reflecting its multinational regulatory footprint.
The TEAD transcription factor family has attracted attention as a downstream node in the Hippo pathway, given the difficulty of directly targeting YAP and TAZ, which lack conventional small-molecule binding pockets. ODM-212’s pan-TEAD profile — covering all TEAD isoforms rather than a single family member — positions it within a small group of assets pursuing this mechanism. Vivace Therapeutics advanced VT3989, a YAP/TEAD inhibitor, into a Phase I trial in mesothelioma, representing one of the earlier clinical data points in this target class. The competitive field remains early-stage, and no TEAD inhibitor has yet reached regulatory approval.